SPN: A Potential Drug Target for Immune System Disorders (G6693)

Target Name: SPN

NCBI ID: G6693

Content of Review Report on SPN Target / Biomarker

SPN

SPN: A Potential Drug Target for Immune System Disorders

SPN, or leukocyte sialoglycoprotein, is a protein that is expressed in the blood cells, particularly leukocytes. It is a type of transmembrane protein that is made up of a glycoprotein chain and a phospholipid tail. The protein is involved in many different processes in the immune system, including the phagocytosis of bacteria and other microorganisms, as well as in the regulation of inflammation.

SPN has been identified as a potential drug target for the treatment of various diseases, including cancer, autoimmune disorders, and infections. Its role in these processes makes it an attractive target for researchers to study and develop new treatments.

One of the main reasons for the potential of SPN as a drug target is its unique structure and biology. SPN is a type of glycoprotein, which means that it is composed of a protein chain that is coated with a layer of phospholipids. This structure gives SPN's stability and long half-life allow it to exist in the blood for longer periods of time, thereby increasing its potential as a drug target.

SPN is also involved in many different signaling pathways in the immune system, which makes it an attractive target for drugs that can modulate these signaling pathways. For example, SPN has been shown to be involved in the regulation of T cell development and function, as well as in the regulation of inflammation. This makes it an attractive target for drugs that can modulate these processes and improve immune function.

SPN has also been shown to be involved in the regulation of cell adhesion and migration. This is important for the development of cancer, as changes in cell adhesion and migration can contribute to tumor progression. Therefore, SPN has also been shown to be a potential Drug targets for treating cancer.

SPN has also been shown to be involved in the regulation of inflammation. This is important for the treatment of autoimmune disorders, as these conditions are characterized by an overactive immune system that can cause inflammation. Therefore, SPN has also been shown to be a potential Drug targets for the treatment of autoimmune diseases.

In addition to its potential as a drug target, SPN is also a potential biomarker for certain diseases. For example, SPN has been shown to be elevated in the blood of people with cancer, and it has been used as a biomarker for monitoring the effectiveness of certain cancer treatments. Additionally, SPN has been shown to be elevated in the urine of people with multiple sclerosis, a disease characterized by the immune system attacking the central nervous system. This suggests that SPN may be a useful biomarker for monitoring the effectiveness of treatments for this disease.

Overall, SPN is a protein that is expressed in the blood cells and is involved in many different processes in the immune system. As a result, it is an attractive target for the development of new drugs for the treatment of various diseases. Its unique structure and biology, as well as its involvement in many different signaling pathways and its potential as a biomarker, make it an intriguing target for research and development.

Protein Name: Sialophorin

Functions: Predominant cell surface sialoprotein of leukocytes which regulates multiple T-cell functions, including T-cell activation, proliferation, differentiation, trafficking and migration. Positively regulates T-cell trafficking to lymph-nodes via its association with ERM proteins (EZR, RDX and MSN) (By similarity). Negatively regulates Th2 cell differentiation and predisposes the differentiation of T-cells towards a Th1 lineage commitment. Promotes the expression of IFN-gamma by T-cells during T-cell receptor (TCR) activation of naive cells and induces the expression of IFN-gamma by CD4(+) T-cells and to a lesser extent by CD8(+) T-cells (PubMed:18036228). Plays a role in preparing T-cells for cytokine sensing and differentiation into effector cells by inducing the expression of cytokine receptors IFNGR and IL4R, promoting IFNGR and IL4R signaling and by mediating the clustering of IFNGR with TCR (PubMed:24328034). Acts as a major E-selectin ligand responsible for Th17 cell rolling on activated vasculature and recruitment during inflammation. Mediates Th17 cells, but not Th1 cells, adhesion to E-selectin. Acts as a T-cell counter-receptor for SIGLEC1 (By similarity)

The "SPN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets